Hospitals Histogenics Corporation Announces Amendment to NeoCart® Phase 3 Clinical Trial Enrollment Criteria byJosh SandbergDecember 22, 2015
Extremities Hospitals TissueGene, Inc. Announces Special Protocol Assessment (SPA) Agreement with the Food and Drug Administration (FDA) for its Phase 3 Clinical Trial of Invossa™ for Patients Suffering from Osteoarthritis of the Knee byJosh SandbergMay 19, 2015
